Key Points
- Major shareholder Tcg Crossover Gp Ii, Llc bought 35,433 shares on March 13 at an average of $24.88 for a total of $881,573.04, increasing its stake to 675,018 shares (a 5.54% ownership rise) valued at about $16.79 million.
- Surrozen (NASDAQ:SRZN) opened at $25.50, trades in a 12‑month range of $5.90–$29.59, has a market cap of $218.54 million, a 50‑day SMA of $23.46 and a 200‑day SMA of $18.20.
- Analyst coverage is mixed — the MarketBeat consensus is a “Moderate Buy” with a $36.00 price target, while individual ratings range from Cantor Fitzgerald’s overweight/$40 target to sell ratings from other firms.
Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) major shareholder Tcg Crossover Gp Ii, Llc acquired 1,190 shares of Surrozen stock in a transaction dated Monday, March 16th. The shares were bought at an average cost of $24.99 per share, with a total value of $29,738.10. Following the transaction, the insider owned 675,613 shares in the company, valued at approximately $16,883,568.87. This trade represents a 0.18% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Tcg Crossover Gp Ii, Llc also recently made the following trade(s):
- On Friday, March 13th, Tcg Crossover Gp Ii, Llc acquired 35,433 shares of Surrozen stock. The stock was bought at an average price of $24.88 per share, with a total value of $881,573.04.
- On Thursday, March 12th, Tcg Crossover Gp Ii, Llc bought 12,374 shares of Surrozen stock. The shares were bought at an average price of $24.99 per share, for a total transaction of $309,226.26.
- On Thursday, February 12th, Tcg Crossover Gp Ii, Llc bought 1,093 shares of Surrozen stock. The shares were bought at an average cost of $23.86 per share, for a total transaction of $26,078.98.
- On Wednesday, February 11th, Tcg Crossover Gp Ii, Llc purchased 17,763 shares of Surrozen stock. The stock was bought at an average price of $23.57 per share, with a total value of $418,673.91.
- On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc purchased 4,355 shares of Surrozen stock. The stock was bought at an average cost of $21.94 per share, with a total value of $95,548.70.
- On Monday, February 2nd, Tcg Crossover Gp Ii, Llc acquired 731 shares of Surrozen stock. The shares were bought at an average price of $21.38 per share, for a total transaction of $15,628.78.
- On Friday, January 30th, Tcg Crossover Gp Ii, Llc acquired 4,271 shares of Surrozen stock. The shares were bought at an average cost of $21.39 per share, for a total transaction of $91,356.69.
Surrozen Price Performance
Shares of SRZN opened at $25.50 on Tuesday. The stock has a 50-day moving average of $23.46 and a 200-day moving average of $18.20. The company has a market cap of $218.54 million, a PE ratio of -1.14 and a beta of 0.53. Surrozen, Inc. has a one year low of $5.90 and a one year high of $29.59.
Hedge Funds Weigh In On Surrozen
A number of hedge funds have recently added to or reduced their stakes in the stock. Braidwell LP bought a new position in shares of Surrozen in the second quarter valued at approximately $1,252,000. Stempoint Capital LP boosted its position in shares of Surrozen by 185.1% during the second quarter. Stempoint Capital LP now owns 686,539 shares of the company's stock valued at $6,138,000 after buying an additional 445,713 shares during the last quarter. Stonepine Capital Management LLC grew its holdings in Surrozen by 7.1% during the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company's stock worth $2,736,000 after buying an additional 20,247 shares in the last quarter. Geode Capital Management LLC raised its position in Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company's stock valued at $277,000 after buying an additional 5,702 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in Surrozen in the 4th quarter valued at $247,000. Institutional investors and hedge funds own 66.57% of the company's stock.
Analyst Upgrades and Downgrades
SRZN has been the subject of a number of research reports. Cantor Fitzgerald assumed coverage on Surrozen in a research note on Thursday, February 19th. They issued an "overweight" rating and a $40.00 price objective for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Surrozen in a report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of Surrozen to a "sell" rating in a research report on Friday, November 28th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $36.00.
Check Out Our Latest Stock Analysis on Surrozen
About Surrozen
(
Get Free Report)
Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.
The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
